NCT05360420 is a NA clinical trial of Immediate CEUS in Liver Cancer, sponsored by Tianjin Third Central Hospital.

Who is sponsoring NCT05360420?

NCT05360420 is sponsored by Tianjin Third Central Hospital.

What drugs are being tested in NCT05360420?

Interventions in NCT05360420: Immediate CEUS.

What condition does NCT05360420 study?

NCT05360420 studies Liver Cancer, Liver Cirrhosis.

Is NCT05360420 still recruiting?

NCT05360420 is currently status unknown. Last updated 13 December 2022.

Last reviewed 2022-12-13 · How we verify

NCT05360420

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnosis of Nodules ≤2 cm Based on US and CEUS Compared With Current Clinical Procedure

Status unknown NA Last updated 13 December 2022

What this trial tests

NA trial testing Immediate CEUS in Liver Cancer in 6,730 participants. Status unknown.

Timeline

26 October 2022

Primary endpoint
1 January 2024

31 December 2024

Quick facts

Lead sponsor	Tianjin Third Central Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	6,730
Start date	26 October 2022
Primary completion	1 January 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Immediate CEUS

Conditions studied

Liver Cancer — all drugs for Liver Cancer →
Liver Cirrhosis — all drugs for Liver Cirrhosis →

Sponsor

Tianjin Third Central Hospital

Who can join

Adults 18 to 80, any sex, with Liver Cancer or Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Due to different etiologies, diagnosis and treatment of HCC in China is different from that in Western countries.US is an important screening method for HCC in patients with liver cirrhosis. CEUS, as an enhanced imaging method based on US, has the advantages of convenience, non-radiation, low cost, short examination time, and the diagnostic performance of HCC is comparable to that of CECT, CEMRI, and hepatobiliary-specific MRI. It is of great significance to consider the cost-effectiveness of each examination based on the principle of cost minimization. Therefore, we propose immediate CEUS examination for suspicious lesions ≤2 cm screened by US, and determine the diagnostic process of further diagnostic methods based on the CEUS results. The aim of this study is to establish a screening and diagnosis process for HCC ≤2 cm suitable for China considering time effect, economic effect and diagnostic efficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting

Other Tianjin Third Central Hospital trials

Trials by the same sponsor.

NCT05361538 — Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm · NA · unknown
NCT04955119 — Fusion Imaging Contrast-enhanced Ultrasound LI-RADS · NA · unknown
NCT04212273 — Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC · NA · unknown
NCT04212286 — Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05360420 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Third Central Hospital
Last refreshed: 13 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05360420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing